Screener
Supernus Pharmaceuticals SUPN License — Revenue recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
FAQ
- What is Supernus Pharmaceuticals's license — revenue recognized?
- Supernus Pharmaceuticals (SUPN) reported license — revenue recognized of $20M in Q1 2026.
- How has Supernus Pharmaceuticals's license — revenue recognized changed year-over-year?
- Supernus Pharmaceuticals's license — revenue recognized increased by 433.3% year-over-year, from $3.75M to $20M.
- What does license — revenue recognized mean?
- This metric represents the total revenue recognized during the reporting period specifically derived from licensing agreements, intellectual property rights, or technology transfer arrangements. It reflects the successful achievement of performance obligations within these contracts, such as the delivery of rights or milestone completions. This figure is a key indicator of the company's ability to monetize its research and development pipeline through strategic partnerships.
Ask your AI about Supernus Pharmaceuticals's license — revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude